1
|
Andersson M, Fröderberg Schooner K, Karlsson Werther V, Karlsson T, De Geer L, Wilhelms DB, Holmbom M, Fredrikson M, Östholm Å, Berg S, Hanberger H. Prehospital lactate analysis in suspected sepsis improves detection of patients with increased mortality risk: an observational study. Crit Care 2025; 29:38. [PMID: 39838391 PMCID: PMC11753079 DOI: 10.1186/s13054-024-05225-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2024] [Accepted: 12/19/2024] [Indexed: 01/23/2025] Open
Abstract
BACKGROUND Rapid, adequate treatment is crucial to reduce mortality in sepsis. Risk stratification scores used at emergency departments (ED) are limited in detecting all septic patients with increased mortality risk. We assessed whether the addition of prehospital lactate analysis to clinical risk stratification tools improves detection of patients with increased risk for rapid deterioration and death in sepsis. METHODS A10-month observational study with consecutive, prospective prehospital inclusion of adult patients with suspected sepsis. Prehospital lactate was used as a continuous variable and in intervals. Analyses of patient subgroups with high and lower priorities according to Rapid Emergency Triage and Treatment System (RETTS) and National Early Warning Score 2 (NEWS2) were performed. Primary outcome was 30-day mortality, secondary outcomes were sepsis at the ED and in-hospital mortality. RESULTS In all, 714 patients were included with a 30-day mortality of 10%. Among the 322 cases (45%) fulfilling Sepsis-3 criteria, the 30-day mortality was 14%. Prehospital lactate was higher among non-survivors (2.6 vs 2.0 mmol/L, p < 0.001). Mortality at different lactate intervals were: 6.7%, at 0-2 mmol/l; 10.0% at > 2-3 mmol/l; 19.2% at > 3-4 mmol/l; and 17.0% at levels > 4 mmol/l. The highest RETTS priority (red) group had higher lactate levels than the lower (non-red) priority group (2.5 vs 1.9 mmol/L, p < 0.001). In the non-red group, prehospital lactate was higher among non-survivors (2.4 vs 1.8 mmol/L, p = 0.002). In the multivariable regression analysis, prehospital lactate > 3 mmol/l was a predictor of 30-day mortality (OR 2.20, p = 0.009) This association was even stronger in the lower priority RETTS non-red group (OR 3.02, p = 0.009). Adding prehospital lactate > 3 mmol/l increased identification of non-survivors from 48 to 68% in the RETTS red group and from 77 to 85% for the NEWS2 ≥ 7 group. CONCLUSION The addition of a prehospital lactate level > 3 mmol/l improved early recognition of individuals with increased mortality risk in a cohort with suspected sepsis admitted to the ED. This was particularly evident in patients whose risk stratification scores did not indicate severe illness. We suggest that the addition of prehospital lactate analysis could improve recognition of subjects with suspected sepsis and increased mortality risk.
Collapse
Affiliation(s)
- Maria Andersson
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Department of Infectious Diseases in Region Östergötland, Linköping University Hospital, Linköping, Sweden.
| | - Karin Fröderberg Schooner
- Department of Infectious Diseases in Region Östergötland, Linköping University Hospital, Linköping, Sweden
| | - Viktor Karlsson Werther
- Department of Infectious Diseases in Region Östergötland, Linköping University Hospital, Linköping, Sweden
| | - Thomas Karlsson
- Department of Emergency Medicine, Vrinnevi Hospital Norrköping, Norrköping, Sweden
| | - Lina De Geer
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- Department of Anaesthesiology and Intensive Care, Linköping University Hospital, Linköping, Sweden
| | - Daniel B Wilhelms
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- Department of Emergency Medicine, Local Health Care Services in Central Östergötland, Region Östergötland, Linköping, Sweden
| | - Martin Holmbom
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- Department of Urology in Östergötland, Linköping University Hospital, Linköping, Sweden
| | - Mats Fredrikson
- Department of Experimental and Clinical Medicine, Linköping University, Linköping, Sweden
| | - Åse Östholm
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- Department of Infectious Diseases in Region Östergötland, Linköping University Hospital, Linköping, Sweden
| | - Sören Berg
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
- Department of Cardiothoracic and Vascular Surgery, Linköping University Hospital, Linköping, Sweden
| | - Håkan Hanberger
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- Department of Infectious Diseases in Region Östergötland, Linköping University Hospital, Linköping, Sweden
| |
Collapse
|
2
|
Määttä S, Petersson C, Gäre BA, Henriks G, Ånfors H, Lundberg C, Nilsagård Y. Experiences of co-producing person-centred and cohesive clinical pathways in the national system for knowledge-based management in Swedish healthcare: a qualitative study. RESEARCH INVOLVEMENT AND ENGAGEMENT 2024; 10:55. [PMID: 38849932 PMCID: PMC11157721 DOI: 10.1186/s40900-024-00565-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Accepted: 03/18/2024] [Indexed: 06/09/2024]
Abstract
BACKGROUND When the 21 Swedish county councils decided to collaborate in the creation of a national system for knowledge-based management, patient participation was mandatory. Patient and next-of-kin representatives (PR) co-produced person-centred and cohesive clinical pathways together with healthcare professionals (HPR). Research on co-production in healthcare at the national level is scarce. The aim of this study is to explore experiences of patient participation from the perspectives of both PRs and HPRs when co-producing clinical pathways within the Swedish nationwide healthcare system for knowledge-based management. METHODS A qualitative study was conducted. A strategic sample of nine PRs and eight HPRs were interviewed individually between August 2022 and January 2023 using a semi-structured interview guide. We analysed data using an inductive content analysis. RESULTS Three main categories were identified: (1) Finding appropriate patient representativeness; (2) Working methods that facilitate a patient perspective; and (3) Influence of the patient perspective in the clinical pathways. CONCLUSIONS The study demonstrates the importance of patient and next-of-kin participation in the construction of clinical pathways at the national level. The results provide a platform for further research on patient participation on the national level and add to studies on if and how patient participation on this level has an impact on how the clinical pathways are put into practice at the micro level, and the support provided at the meso level. The study contributes to the growing body of literature studying patient participation and co-production. TRIAL REGISTRATION Region Örebro County ID 276,940. An advisory opinion was obtained from the Swedish Ethical Review Authority (2021-05899-01).
Collapse
Affiliation(s)
- Sylvia Määttä
- Institute of Health and Care Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Christina Petersson
- Jönköping Academy for Improvement of Health and Welfare, Jönköping University, Center for Learning and Innovation at Region Jönköping County, Sweden, Sweden.
| | - Boel Andersson Gäre
- Jönköping Academy for Improvement of Health and Welfare, Jönköping University, Sweden and Futurum, Region Jönköping County, Jönköping, Sweden
| | - Göran Henriks
- Yerevan State University, Strategic Advisor Region Jönköping County, Yerevan, Sweden
| | - Henrik Ånfors
- Qulturum - Center for Learning and Innovation, Region Jönköping County, Jönköping, Sweden
| | | | - Ylva Nilsagård
- University Healthcare Research Centre, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
| |
Collapse
|
3
|
Eberhard A, Mellhammar L. Extended-spectrum beta-lactamase-producing Enterobacterales in patients with suspected sepsis in an acute care setting in Skåne, Sweden: a cohort study. Infect Dis (Lond) 2024; 56:285-292. [PMID: 38163931 DOI: 10.1080/23744235.2023.2299676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 12/22/2023] [Indexed: 01/03/2024] Open
Abstract
INTRODUCTION Epidemiological data on extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales are most often based on microbiological laboratory isolates and do not consider important clinical data such as infection or colonisation, treatment, and outcome. This study aimed to assess prevalence of ESBL-producing Enterobacterales as the cause of infection in patients with suspected sepsis in the emergency department based on clinical data. It also examined the number of patients with suspected sepsis who had ESBL-producing pathogens, comparing estimates that were based on laboratory data versus a combination of laboratory and clinical data. METHODS Patients with suspected sepsis in the emergency department at Skåne University Hospital, Lund, Sweden were included consecutively. Data were collected retrospectively from medical records. RESULTS Of the 764 included patients, 223 patients had growth of Enterobacterales in any specimen (i.e. colonisation or infection according to laboratory data), while 191 patients had Enterobacterales detected in the blood or in the suspected focus of infection (i.e. an infection according to clinical and laboratory data). Eighteen patients had ESBL-producing Enterobacterales in any clinical specimen, 11 of whom had an infection with ESBL-producing Enterobacterales, resulting in a prevalence of infections with ESBL-producing Enterobacterales in infected patients with suspected sepsis of 1.8%. The number of patients with ESBL-producing Enterobacterales was not significantly different when infection was defined using laboratory data alone versus a combination of laboratory and clinical data [18/223 (8.1%) vs 11/191 (5.8%), p = 0.36]. CONCLUSIONS The prevalence of ESBL-producing Enterobacterales infections among patients with suspected sepsis is low in an acute care setting in Sweden.
Collapse
Affiliation(s)
- Arvid Eberhard
- Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden
| | - Lisa Mellhammar
- Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden
| |
Collapse
|